Please login to the form below

Not currently logged in


This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

MSD taps Austria’s Themis to bolster vaccine pipeline

MSD taps Austria’s Themis to bolster vaccine pipeline

on immuno-oncology blockbuster Keytruda (pembrolizumab) which is currently driving its growth and currently makes up around a fifth of revenues.

Latest news

More from news
Approximately 74 fully matching, plus 282 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    its role in developing immuno-oncology blockbuster Keytruda. ... Commenting on her colleague, Susan Galbraith, head of oncology at AstraZeneca’s IMED Biotech unit (and herself one of our listed leaders last year), said: “Ruth has helped transform

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However, the company continues to study Opdivo in trials twinned with a very wide range of novel agents, with the hope of finding a combination which can take immuno-oncology (IO)

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    By Chris Learn and Martin Lachs. The immuno-oncology (IO) field is becoming incredibly crowded and competitive. ... Chris Learn is Program Manager and Martin Lachs is VP Project Management, both at Oncology Haematology, ICON plc.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Merck/MSD looks to have gained a dominant position in checkpoint

  • Is China ready for a pharmaceutical gold rush?

    China has long been a leader in pharmaceutical manufacturing and export.But with the news that the country has approved its first immuno- oncology (I-O) treatment comes the hope that ... Professor Yi-Long Wu, a tenured director of Guangdong General

More from intelligence
Approximately 3 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest from PMHub

  • Lucid Group strengthens its scientific leadership and client service team with two new hires

    editorial. With expertise in COPD, oncology and behaviour-change patient support programmes Eva is a magical addition to the team. ... Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases.

  • SWITCHED ONcology

    We are stronger together. We are Switched ON. Switched ONcology is the latest thought leadership campaign from the award-winning Havas lynx portfolio. ... The campaign provides our partners with deeper insight, smarter ideas and more meaningful

  • 18 SWITCHED ONcology: The Big Communication

    Matching unprecedented clinical advances in immuno-oncology with transformative communication. Cancer. One of the most powerful words in the English dictionary. ... This new movement towards unleashing the body’s own defences against rogue cancer cells

  • Medical information in precision medicine

    We are not treating the partnership as just another oncology medicine – it’s a molecular information service, and that requires a great level of scientific understanding.

More from PMHub
Approximately 18 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....